Realta Life Sciences secured an additional $40 million in the final tranche of its Series A funding for its hypoxic ischemic encephalopathy (HIE) treatment. The round brings Realta’s total raised to more than $150 million, using mission-driven investors alongside a family-office model. HIE affects infants after reduced oxygen and blood flow to the brain, and it remains a high-need indication with limited effective interventions. Funding for late-stage preclinical-to-clinical transition is particularly critical because HIE studies can require complex neonatal trial execution. Realta’s financing signals continued investor focus on neuroprotective approaches where target patient populations are clearly defined and endpoints can be aligned to meaningful neurologic outcomes. For investors, the company’s ability to keep funding momentum after an initial Series A suggests confidence in execution capacity and a credible path to clinical progression.